International Journal of Endocrinology and Metabolism

Published by: Kowsar

Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran

Shahrzad Mohseni 1 , Maryam Aboeerad 1 , Farshad Sharifi 2 , Seyed Mohammad Tavangar 3 , * and Mohammadreza Mohajeri-Tehrani 1 , **
Authors Information
1 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Pathology, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Corresponding Authors:
Article information
  • International Journal of Endocrinology and Metabolism: In Press (In Press); e81983
  • Published Online: April 13, 2019
  • Article Type: Research Article
  • Received: July 11, 2018
  • Revised: March 2, 2019
  • Accepted: February 26, 2019
  • DOI: 10.5812/ijem.81983

To Cite: Mohseni S, Aboeerad M, Sharifi F, Tavangar S M, Mohajeri-Tehrani M. Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran, Int J Endocrinol Metab. Online ahead of Print ; In Press(In Press):e81983. doi: 10.5812/ijem.81983.

Copyright © 2019, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24):2558-73. doi: 10.1056/NEJMra062453. [PubMed: 17167139].
  • 2. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398. doi: 10.1155/2012/540398. [PubMed: 22518126]. [PubMed Central: PMC3296170].
  • 3. Haliloglu O, Kuruoglu E, Ozkaya HM, Keskin FE, Gunaldi O, Oz B, et al. Multidisciplinary approach for acromegaly: A single tertiary center's experience. World Neurosurg. 2016;88:270-6. doi: 10.1016/j.wneu.2015.12.092. [PubMed: 26806060].
  • 4. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247-71. doi: 10.1210/er.2010-0002. [PubMed: 21123741].
  • 5. Kasuki L, Dalmolin MD, Wildemberg LE, Gadelha MR. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol (Oxf). 2018;88(6):889-95. doi: 10.1111/cen.13595. [PubMed: 29520805].
  • 6. Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235-47. doi: 10.1007/s11102-015-0684-z. [PubMed: 26519143]. [PubMed Central: PMC4858561].
  • 7. Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M. Octreotide LAR treatment of acromegaly in "real life": Long-term outcome at a tertiary care center. Pituitary. 2015;18(3):290-6. doi: 10.1007/s11102-014-0570-0. [PubMed: 24781039].
  • 8. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152(3):379-87. doi: 10.1530/eje.1.01863. [PubMed: 15757854].
  • 9. Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X, et al. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol. 2004;150(6):763-71. doi: 10.1530/eje.0.1500763. [PubMed: 15191345].
  • 10. Hentschel SJ, McCutcheon l E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003;30(3):215-9. doi: 10.1017/S0317167100002614. [PubMed: 12945944].
  • 11. Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM. Non-functioning pituitary adenoma: Immunohistochemical analysis of 85 cases. Folia Neuropathol. 2007;45(2):72-7. [PubMed: 17594597].
  • 12. Sarkar S, Chacko AG, Chacko G. Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas. J Clin Neurosci. 2015;22(7):1173-7. doi: 10.1016/j.jocn.2015.01.029. [PubMed: 25979255].
  • 13. Ceccato F, Regazzo D, Barbot M, Denaro L, Emanuelli E, Borsetto D, et al. Early recognition of aggressive pituitary adenomas: A single-centre experience. Acta Neurochir (Wien). 2018;160(1):49-55. doi: 10.1007/s00701-017-3396-5. [PubMed: 29170844].
  • 14. Babu H, Ortega A, Nuno M, Dehghan A, Schweitzer A, Bonert HV, et al. Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery. 2017;81(2):357-66. doi: 10.1093/neuros/nyx020. [PubMed: 28368500].
  • 15. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab. 2008;93(7):2746-50. doi: 10.1210/jc.2008-0126. [PubMed: 18460561].
  • 16. Alimohamadi M, Ownagh V, Mahouzi L, Ostovar A, Abbassioun K, Amirjmshidi A. The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study. Asian J Neurosurg. 2014;9(3):130-6. doi: 10.4103/1793-5482.142732. [PubMed: 25685203]. [PubMed Central: PMC4323896].
  • 17. Sarkar S, Chacko AG, Chacko G. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir (Wien). 2014;156(12):2221-30. discussion 2230. doi: 10.1007/s00701-014-2230-6. [PubMed: 25238988].
  • 18. Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, et al. A classification tree approach for pituitary adenomas. Hum Pathol. 2012;43(10):1627-37. doi: 10.1016/j.humpath.2011.12.003. [PubMed: 22446019].
  • 19. Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. doi: 10.1210/jc.2014-2700. [PubMed: 25356808].
  • 20. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-8. doi: 10.1210/jc.2009-2670. [PubMed: 20410227].
  • 21. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, et al. Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci. 2005;20(3):489-94. doi: 10.3346/jkms.2005.20.3.489. [PubMed: 15953875]. [PubMed Central: PMC2782209].
  • 22. Schaller B. Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study. Pituitary. 2002;5(4):247-53. doi: 10.1023/A:1025329900839. [PubMed: 14558673].
  • 23. Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, et al. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 2004;146(8):831-9. doi: 10.1007/s00701-004-0298-0. [PubMed: 15254805].
  • 24. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: Secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9(2):103-13. doi: 10.1677/erc.0.0090103. [PubMed: 12121834].
  • 25. Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C. MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology. 1992;34(1):43-51. doi: 10.1007/BF00588432. [PubMed: 1553037].
  • 26. Iuchi T, Saeki N, Osato K, Yamaura A. Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien). 2000;142(12):1345-51. doi: 10.1007/s007010070003. [PubMed: 11214627].
  • 27. Botelho CH, Magalhaes AV, Mello PA, Schmitt FC, Casulari LA. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr. 2006;64(1):60-6. [PubMed: 16622555].
  • 28. Sarkar S, Rajaratnam S, Chacko G, Chacko AG. Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg. 2014;126:190-5. doi: 10.1016/j.clineuro.2014.09.004. [PubMed: 25278017].
  • 29. van Bunderen CC, van Varsseveld NC, Baayen JC, van Furth WR, Aliaga ES, Hazewinkel MJ, et al. Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: Patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary. 2013;16(2):158-67. doi: 10.1007/s11102-012-0395-7. [PubMed: 22535510]. [PubMed Central: PMC3659272].
  • 30. Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine. 2018;60(3):415-22. doi: 10.1007/s12020-018-1590-8. [PubMed: 29626274].
  • 31. Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. J Neurol Surg B Skull Base. 2014;75(1):47-52. doi: 10.1055/s-0033-1354578. [PubMed: 24498589]. [PubMed Central: PMC3912146].
  • 32. Jane JA, Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. Endoscopic transsphenoidal surgery for acromegaly: Remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9):2732-40. doi: 10.1210/jc.2011-0554. [PubMed: 21715544].
  • 33. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett. 2010;31(6):823-8. [PubMed: 21196926].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments